PMID- 35846304
OWN - NLM
STAT- MEDLINE
DCOM- 20220719
LR  - 20220802
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A 
      Meta-Analysis.
PG  - 920857
LID - 10.3389/fendo.2022.920857 [doi]
LID - 920857
AB  - BACKGROUND: Lenvatinib has shown promising efficacy in targeted therapies that 
      have been tested to treat anaplastic thyroid carcinoma (ATC) in both preclinical 
      and clinical studies. The aim of this study was to evaluate the efficacy and 
      safety of lenvatinib in the treatment of patients with ATC. METHODS: PubMed, the 
      Cochrane Library, Embase, and ClinicalTrials.gov were searched for potential 
      eligible studies from inception to February 1, 2022. The outcomes included 
      partial response (PR), stable disease (SD), disease control rate (DCR), median 
      progression-free survival (mPFS), and median overall survival (mOS). Effect sizes 
      for all pooled results were presented with 95% CIs with upper and lower limit. 
      RESULTS: Ten studies met the inclusion criteria. The aggregated results showed 
      that the pooled PR, SD, and DCR were 15.0%, 42.0%, and 63.0%, respectively. The 
      pooled mPFS and mOS were 3.16 (2.18-5.60) months and 3.16 (2.17-5.64) months, 
      respectively. Furthermore, PFS rate at 3 months (PFSR-3m), PFSR-6m, PFSR-9m, 
      PFSR-12m, and PFSR-15m were 52.0%, 22.5%, 13.9%, 8.4%, and 2.5%, respectively. 
      Meanwhile, the 3-month OS rate (OSR-3m), OSR-6m, OSR-9m, OSR-12m, and OSR-15m 
      were 64.0%, 39.3%, 29.7%, 18.9%, and 14.2%, respectively. The most common adverse 
      events (AEs) of lenvatinib were hypertension (56.6%), proteinuria (32.6%), and 
      fatigue (32%). CONCLUSIONS: This meta-analysis showed that lenvatinib has 
      meaningful antitumor activity, but limited clinical efficacy in ATC. SYSTEMATIC 
      REVIEW REGISTRATION: PROSPERO [https://www.crd.york.ac.uk/PROSPERO/], identifier 
      [CRD42022308624].
CI  - Copyright (c) 2022 Huang, Zhang, Zheng and Gao.
FAU - Huang, Dongmei
AU  - Huang D
AD  - Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute 
      and Hospital, National Clinical Research Center for Cancer, Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, 
      Tianjin, China.
FAU - Zhang, Jinming
AU  - Zhang J
AD  - Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute 
      and Hospital, National Clinical Research Center for Cancer, Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, 
      Tianjin, China.
FAU - Zheng, Xiangqian
AU  - Zheng X
AD  - Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute 
      and Hospital, National Clinical Research Center for Cancer, Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, 
      Tianjin, China.
FAU - Gao, Ming
AU  - Gao M
AD  - Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute 
      and Hospital, National Clinical Research Center for Cancer, Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, 
      Tianjin, China.
AD  - Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, Tianjin, 
      China.
AD  - Tianjin Key Laboratory of General Surgery Inconstruction, Tianjin Union Medical 
      Center, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220630
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects/therapeutic use
MH  - Humans
MH  - *Phenylurea Compounds/adverse effects/therapeutic use
MH  - *Quinolines/adverse effects/therapeutic use
MH  - *Thyroid Carcinoma, Anaplastic/drug therapy/pathology
MH  - *Thyroid Neoplasms/drug therapy/pathology
PMC - PMC9279913
OTO - NOTNLM
OT  - anaplastic thyroid carcinoma
OT  - efficacy
OT  - lenvatinib
OT  - meta-analysis
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/19 06:00
MHDA- 2022/07/20 06:00
PMCR- 2022/01/01
CRDT- 2022/07/18 04:00
PHST- 2022/04/15 00:00 [received]
PHST- 2022/05/31 00:00 [accepted]
PHST- 2022/07/18 04:00 [entrez]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.920857 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Jun 30;13:920857. doi: 
      10.3389/fendo.2022.920857. eCollection 2022.